Technavio, a tech-focused market research firm, has published a new report on the global next-generation biologics market, which is expected to experience a steady growth rate with a CAGR of more than 14% during the forecast period 2016-2020.
This latest report by Technavio covers the market outlook and growth prospects of the global next-gen biologics market for 2016-2020, considering 2015 as the base year. In addition, an overview of the market, key leading countries, vendor landscape, and a detailed analysis of the top vendors operating in this market are covered in the report.
Based on geographical division, Technavio market researchers segment the global next-gen biologics market into the following key regions: Americas, EMEA, and APAC.
Geographical segmentation of the global next-generation market for 2015 (market share %)
|
Americas |
53.55% |
|
EMEA |
29.80% |
|
APAC |
16.65% |
Source: Technavio
The Americas: largest revenue generating region for next-gen biologics
The growth of the next-generation biologics market in the Americas accounted for almost 54% of the global market during 2015. The rapid-growth of the market in Americas is fueled by the increasing prevalence of cancer, autoimmune diseases, metabolic diseases, musculoskeletal disorders, central nervous system (CNS) disorders, and blood disorders in the region. According CDC research studies, the number of new cases of solid tumors diagnosed in 2016 in the US is likely to be more than 150 million, and the number of deaths from the disease is estimated to be in the range of 580,000 to 590,000. As per CDC, about 20,000 individuals in the US are diagnosed with hemophilia, of which around 75%-85% of them have hemophilia A. CDC also indicated that around 400 newborns in the US are affected by hemophilia each year. The higher uptake of existing biologics and the launch of new ones in the region are also expected to act as incentive for growth of the next-gen biologics market in the Americas during the forecast period.
According to Sapna Jha, a lead analyst at Technavio for cardiovascular diseases, “There is an increased focus on the development of oral insulin therapies due to the concerns associated with insulin injections. Individuals who self-inject are concerned about the risks of needle stick injuries and the safe disposal of the used product. The oral form of insulin prevents the unpleasantness of insulin injections and other complications associated with the existing therapies. Oramed Pharmaceuticals and Generex Biotechnology are developing oral insulin therapies to overcome the drawbacks of the current therapies.”
Click here to request a free sample of this report
Next-gen biologics market in EMEA
During 2015, the next-gen biologics market in EMEA accounted for almost 30% of the global market and is expected to undergo substantial growth during the forecast period. The market is expected to witness high growth-rate in countries such as the Germany, the UK, Spain, France, and Italy. The increased number of drug approvals in the region is expected to increase the uptake of the drugs, leading to the market’s growth. During the forecast period, the next-generation biologics market is expected to benefit from the increased focus on the development of regenerative medicine. For instance, in Germany, the Regenerative Medicine Initiative Germany is associated with a few players in the market to develop strategy in clinical applications. Many institutes in Germany are partnering with the US to develop cell therapy products.
Next-gen biologics market in APAC
The next-gen biologics market in APAC is projected to experience rapid growth during the forecast period. The growth of the market in this region is attributable to better market penetration of biologics in emerging economies, especially in Australia, India, Japan, China and South Korea. Furthermore, the rising number of initiatives undertaken by major vendors in assisting individuals is propelling the sales of next-gen biologics in many APAC countries. For instance, the Pharmaceutical Affairs Law in Japan amended Pharmaceutical and Medical Devices Law in 2014, under which rapid approval for regenerative medicine will be provided for a new product category. This amendment has widened the opportunity for many vendors who are conducting clinical trials for the approval of their product.
The leading vendors operating in the global next-generation biologics market are:
- F. Hofmann-La Roche
- Novo Nordisk
- Sanofi
- Takeda Pharmaceuticals
Other prominent vendors in the market include Aastrom Biosciences, AbbVie, AbGenomics, Acologix, ADC Therapeutics, Adocia, Agensys, AlloCure, AlloSource, ALMAC Group, Alphatec Spine, Ambrx, Amorcyte, Argos Therapeutics, Astellas Pharma, AstraZeneca, Athersys, Avita Medical, Baxter, Bayer HealthCare, Bellicum Pharmaceuticals, BioCardia, Biocon, Biodel, BIOGENOMICS, BioLife Solutions, BioRestorative Therapies, BioTissue Technologies, Bluebird Bio, Boehringer Ingelheim, BrainStorm Cell Therapeutics, Calimmune, Capricor, CARBOGEN AMCIS, Cell Medica, Celldex Therapeutics, Celyad, Cesca, CryoLife, CSL Behring, Cynata Therapeutics, Daiichi Sankyo, Dance Biopharm, Dendreon, Diasome Pharmaceuticals, DiscGenics, Endo Pharmaceuticals, Esperance Pharmaceuticals, Exsulin, Fate Therapeutics, Fibrocell Science, Formation Biologics, Forticell Bioscience, Fortress Biotech, Gamida Cell, GENEREX, Genmab, Geron, GlaxoSmithKline, Harvard Apparatus Regenerative Technology, Healthpoint, Histogen, Histogenics, Humacyte, Immunocellular Therapeutics, Immunogen, Integra LifeSciences, InVivo Therapeutics, ISTO Technologies, Juno Therapeutics, Juventas Therapeutics, Kairos Therapeutics, Kensey Nash, Kiadis Pharma, Kinetic Concept, Living Cell Technologies, MacroGenics, MannKind, MaxCyte, MedImmune, Medtronic, Mersana Therapeutics, Mesoblast, MiMedx, Nanofiber Solutions, Nanotope, Neuralstem, NewLink Genetics, NGM Biopharmaceuticals, Northwest Biotherapeutics, Novartis, NovaRx, Ocata Therapeutics, Opexa Therapeutics, Oramed Pharmaceuticals, Organovo, Orteq, Orthofix, Osiris Therapeutics, Osteotech, OXFORD BioTherapeutics, Pfizer, PhaseBio Pharmaceuticals, Pluristem Therapeutics, Prima BioMed, Q Therapeutics, ReproCELL, RhinoCyte, RTI Surgical, SanBio, Sangamo, Shire Regenerative Medicine, STEMCELL Technologies, Stemcentrx, Stratatech, Synthon Biopharmaceuticals, TEI Biosciences, Tengion, Thermalin Diabetes, TiGenix, Tissue Genesis, TissueGene, Tolerion, VentriNova, Vericel, VeroScience, ViaCyte, VistaGen Therapeutics, vTv Therapeutics, Wockhardt, XOMA, Zimmer-Biomet, and Zymeworks.
A more detailed analysis is available in the Technavio report tilted, ‘Global Next-generation Biologics Market 2016-2020’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Biologic Therapeutics Market 2015-2019
- Global Agricultural Biologicals Market 2016-2020
- Global Spine Biologics Market 2016-2020
- Global Wound Biologics Market 2016-2020
To read more press releases- click here.
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
https://www.technavio.com/
